<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463423</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-22600</org_study_id>
    <secondary_id>SU-10202011-8537</secondary_id>
    <secondary_id>IRB-22600</secondary_id>
    <secondary_id>LUN0048</secondary_id>
    <nct_id>NCT01463423</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)</brief_title>
  <official_title>Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study of a procedure to treating lung cancer with focused radiation called&#xD;
      Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the&#xD;
      effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR&#xD;
      based on tumor-specific factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: Evaluate local tumor control with individually-optimized lung tumor&#xD;
      stereotactic ablative radiotherapy (SABR). Tumor control will be assessed by CT, PET-CT, and&#xD;
      if appropriate, biopsy. The trial will focus on three cohorts: 1) patients with limited&#xD;
      primary NSCLCs (T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0) non-small cell lung cancer; 2)&#xD;
      patients with a history of NSCLC who have new limited primary NSCLC lesion(s); and 3)&#xD;
      patients with more advanced lung cancer or lung metastases from a variety of different&#xD;
      cancers.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Evaluate the toxicity of individually optimized lung tumor SABR. Pulmonary, esophageal,&#xD;
           chest wall, skin, vascular, cardiac/pericardial, and neurologic (brachial&#xD;
           plexus/recurrent laryngeal/myelitis) toxicity will be scored by the CTCAE 4.0 criteria.&#xD;
&#xD;
        -  Evaluate the feasibility of anatomically optimized audio-visual biofeedback&#xD;
           (AVB)-coached breath-hold technique assisted by fast delivery using gated RapidArc with&#xD;
           flattening free filter mode (FFF) in a subset of patients. Feasibility will be assessed&#xD;
           based on: i) The proportion of patients able to reproduce an anatomically-optimized&#xD;
           breath-hold with AVB-coaching during treatment. ii) The reduction in treatment delivery&#xD;
           time compared to gated free-breathing treatment.&#xD;
&#xD;
        -  Determine progressio-free, metastasis-free, and overall survival in patients treated&#xD;
           with individually-optimized lung tumor SABR.&#xD;
&#xD;
        -  Examine new biomarkers in lung tumor SABR patients.&#xD;
&#xD;
      This is a study of the procedure stereotactic ablative radiotherapy (SABR). It is not a study&#xD;
      of a specific drug or device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 7, 2021</completion_date>
  <primary_completion_date type="Actual">January 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate local tumor control with individually optimized lung tumor Stereotactic Ablative Radiotherapy (SABR). Tumor control will be assessed by CT, PET-CT, and if appropriate, biopsy.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in toxicity from baseline of individually optimized lung tumor SABR</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of anatomically optimized audio-visual biofeedback (AVB)-coached breath-hold technique assisted by fast delivery using gated RapidArc with flattening free filter mode (FFF) in a subset of patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine new biomarkers in lung tumor SABR patients.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine progression free survival in patients treated with individually optimized lung tumor SABR.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine metastasis free survival in patients treated with individually optimized lung tumor SABR.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine overall survival in patients treated with individually optimized lung tumor SABR.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Limited primary NSCLCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with limited primary NSCLCs (T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0) non-small cell lung cancer;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>History of NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with a history of NSCLC who have new limited primary NSCLC lesion(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced lung cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with more advanced lung cancer or lung metastases from a variety of different cancers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Individualized Stereotactic Ablative Radiotherapy (iSABR)</intervention_name>
    <description>Individualized stereotactic ablative radiotherapy (iSABR) is a radiotherapy procedure.</description>
    <arm_group_label>Advanced lung cancer</arm_group_label>
    <arm_group_label>History of NSCLC</arm_group_label>
    <arm_group_label>Limited primary NSCLCs</arm_group_label>
    <other_name>SABR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Limited primary NSCLCs (T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0) or metastatic&#xD;
             lung tumors with no evidence of uncontrolled extrathoracic metastases.&#xD;
&#xD;
          -  Up to 4 lesions may be included. For a single lesion the sum of three orthogonal&#xD;
             diameters can be no more than 20 cm. For multiple lesions, no lesion can have a sum of&#xD;
             orthogonal diameters greater than 15 cm.&#xD;
&#xD;
          -  Both peripheral and central tumors are accepted for this trial.&#xD;
&#xD;
          -  Age &gt; = 18 years old&#xD;
&#xD;
          -  Both men and women and members of all races and ethnic groups are eligible for this&#xD;
             trial.&#xD;
&#xD;
          -  Note: Patients may be enrolled more than once (eg, for a new tumor)&#xD;
&#xD;
          -  Both men and women and members of all races and ethnic groups are eligible for this&#xD;
             trial.&#xD;
&#xD;
          -  Note: Patients may be enrolled more than once (e.g. for a new tumor)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of uncontrolled extrathoracic metastases&#xD;
&#xD;
          -  Contraindication to receiving radiotherapy&#xD;
&#xD;
          -  Age &lt; 18 years old.&#xD;
&#xD;
          -  Pregnant and breastfeeding women are excluded&#xD;
&#xD;
          -  Prior radiation therapy is allowed but there should not be overlap with the prior high&#xD;
             dose regions unless approved by the protocol directors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maximilian Diehn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bill Loo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2011</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

